Henry Schein stock falls 2.72 percent despite higher guidance

Henry Schein stock fell 2.72 percent to USD 85.05 on Nasdaq on September 23, 2026, even as the healthcare distributor raised its 2026 outlook. The share price stood 7.74 percent below its 52-week high of USD 92.18, placing the market reaction against a stronger operating forecast.

Revenue beats the estimate

Henry Schein generated USD 3.458 billion in Q2 2026 revenue, up 6.7 percent from Q2 2025. According to Yahoo Finance, the result exceeded the USD 3.373853 billion consensus estimate by 2.5 percent.

Adjusted diluted EPS reached USD 1.27 in Q2 2026, compared with USD 1.10 a year earlier and a USD 1.22 estimate. That means adjusted EPS grew 15.5 percent year over year and exceeded consensus by 4.1 percent, giving the quarterly figures more weight than the one-day decline.

Guidance moves higher

Management now expects 2026 total sales growth of 4.5%-5.5% over 2025, compared with its earlier 3%-5% range. The updated non-GAAP diluted EPS outlook is USD 5.29-5.39, representing 6%-8% growth from the 2025 base of USD 4.97, according to Yahoo Finance.

The guidance range also excludes additional remeasurement gains for the rest of 2026. Henry Schein expects USD 11 million of remeasurement gains in 2026, while the comparable 2025 total was USD 38 million, so the revised earnings range emphasizes underlying operating growth rather than one-time benefits.

Stock remains below yearly high

Henry Schein stock traded at USD 85.05 on Nasdaq on September 23, 2026, down USD 2.38 from the previous close of USD 87.43. The 52-week range was USD 61.95 to USD 92.18, while market capitalization stood at USD 9.68864085 billion on the same date.